Skip to main content Accessibility help

Cardiovascular Side Effects of Novel Antipsychotics

  • Sanjay Gupta, Prakash S. Masand and Ashok J. Kothari


Since the introduction of clozapine, several novel antipsychotic agents have been introduced and more are in Phase II/III studies. Because these agents are used clinically as first-line treatment, we need to be more familiar with their side-effect profiles. This manuscript reviews the cardiovascular side effects of currently available novel antipsychotics. The medications reviewed include clozapine, risperidone, olanzapine, quetiapine, and ziprasidone. Guidelines are suggested for the use of these medications in clinical practice.


Corresponding author

Please direct correspondence to: Sanjay Gupta, MD, Department of Psychiatry, Olean General Hospital, 515 Main Street, Olean, NY 14760. Tel: 716-373-1094; Fax: 716-373-1153; E-mail:


Hide All
1. Gury, C, Canceil, O, Laria, P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale. 2000;26:6272.
2. Reilly, JG, Ayis, SA, Ferrier, IN. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:10481052.
3. Moss, AJ. Measurement of QT ihterval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993;72:238258.
4. Fayek, M, Kingsbury, SJ, Simpson, GM, Zada, J. Cardiac effects of antipsychotics medications. Psychiatr Serv. 2001;52:607609.
5. American Psychiatric Association. Sudden Death in Psychiatric Patients: The Role of Neuroleptic Drugs. Task Force Report 27. Washington, DC: American Psychiatric Association; 1987.
6. Faber, TS, Zehender, M, Just, H. Drug-induced torsades de pointes: incidence management and prevention. Drug Saf. 1994;11:463476.
7. Welch, R, Chue, P. Antipsychotic agents and QT changes. J Psychiatry Neurosci. 2000;25:154160.
8. Selzer, A, Wray, HW. Quinidine syncope: paroxysmal ventricular fibrillation occur-ring during treatment of chronic atrial arrhythmias. Circulation. 1964;30:1726.
9. Rodem, DM, Woosley, RL, Primm, R.K.Incidence and clinical features of quinidine associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:10881093.
10. Kay, GN, Plumb, VJ, Arciniegas, JG, et al. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806817.
11. Bauman, JL, Bauernfeind, RA, Hoff, JV, et al. Torsades de pointes due to quinidine: observations in 31 patients. Am Heart J. 1984;107:425430.
12. Torp-Pederson, C, Moller, M, Bloch-Thomsen, PE, et al. The Danish investigation of arrhythmia and mortality on dofetilide study group: dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:679911.
13. Stambler, BS, Wood, MA, Ellen Bogen, KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter to fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:16131621.
14. Haverkamp, W, Breithardt, G, Camm, AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmie drugs: clinical and regulatory implications. Eur Heart J. 2000;21:12161231
15. Thioridazine HC1 [package insert]. East Hanover. INJ: Novartis Pharmaceuticals Corporation; 2000.
16. Serentil [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2000.
17. Barnett, AA. Safety concerns over antipsychotic drug sertindole. Lancet. 1996;348:256
18. Jann, MW. Clozapine. Pharmacotherapy. 1991;11:179195.
19. Coward, DM. General pharmacology of clozapine. Br J Psychiatry. 1992;160(suppll7):511.
20. Lieberman, JA, Kane, JM, Johns, CA. Clozapine: guidelines for clinical management. J Clin Psychiatry. 1989;50:329338.
21. Lieberman, JA, Safferman, A. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Q. 1992;63:314.
22. Marder, SR. Adverse effects of clozapine [monograph]. J Clin Psychiatry. 1996;14:1112.
23. Gupta, S, Rajaprabhakaran, R. Clozapine-induced hypertension. Am J Psychiatry. 1994;151;148.
24. Jens, G, Kilian, K, Kerr, C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:18411845.
25. Bandelow, B, Degner, D, Kreusch, U, et al. Myocarditis under therapy with clozapine. Schizophr Res. 1995;17:293294.
26. Leo, RJ, Kreeger, JL, Kim, KY. Cardiomyopalhy associated with clozapine. Ann Pharmacother. 1996;30:603605.
27. Kang, UG, Kwoon, JS, Ahn, MA, et al. Electrographic abnormalities in patients treated with clozapine. J Clin Psychiatry. 2000:61:441446.
28. Beale, MD, Pritchett, JT, Kellner, CH. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine. Convuls Ther. 1994;10:228231.
29. Maynes, D. Bilateral pulmonary embolism in a patient on clozapine therapy. Can J Psychiatry. 2000;45:296297.
30. Hagg, S, Spigset, O, Soderstrom, TG. Association of venous thromboemholism and clozapine. Lancet. 2000;355:11551156.
31. Lacika, S, Cooper, JP. Pulmonary embolus possibly associated with clozapine treatment. Can J Psychiatry. 1999;44:396397.
32. Ihde-Scholl, T, Rolli, ML, Jefferson, JW. Clozapine and pulmonary embolus. Am J Psychiatry. 2001;158:499500.
33. Coodin, S, Ballegeer, T. Clozapine therapy and pulmonary embolism. Can J Psychiatry. 2000;45:395.
34. Walker, AM, Lanza, LL, Arellana, F, Rothman, KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8:671677.
35. Clardy, J, Gule, RH. Mortality risk and clozapine. Am J Psychiatry. 1995;152:161.
36. Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825835.
37. Gupta, S, Black, DW, Smith, D. Risperidone: review of its pharmacology, and therapeutic use in schizophrenia. Ann Clin Psychiatry. 1994;6:173180.
38. Madhusoodanan, S, Brecher, M, Brenner, R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Amer J Geriatr Psychiatry. 1999;7:132138.
39. Min, SK, Rhee, CS, Kim, CE, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel-group, double-blind comparative trial. Yonsei Med J. 1997;31:967–870.
40. Hatta, K, Takashashi, T, Nakamura, H, et al. The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol. 2001;21:257261.
41. Ravin, DS, Levenson, JM. Fatal cardiac event following initiation of risperi-done therapy. Ann Pharmacother. 1997;31:967–870.
42. Chong, SA, Tan, CH, Lee, HS. Atrial ectopics with clozapine-risperidone combination. J Clin Psychopharmacol. 1997;17:130131.
43. Pfizer, Inc. Study Report of Ziprasidone Clinical Pharmacology Protocol. 2000. Rockville, MD: Food and Drug Administration Center for Drug Evaluation and Research Division of Cardiorenal Drug Products Consultation; 2000.
44. Lemmens, P, Brecher, M, Baelen, BV. Tolerability and cardiovascular safety of risperidone. Acta Psychiatrica Scand. 1999;99:160170.
45. Gupta, S, Masand, PS. Olanzapine: review of its pharmacology and indications in clinical practice. Primary Psychiatry. 1997;4:7381.
46. Czekalla, J, Beasley, CM Jr, Dellva, MA, et al. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry. 2001;62:191198.
47. Masand, PS, Gupta, S. Long term side effects of novel antipsychotics. Journal of Psychiatric Practice. 2000;6:299309.
48. Casey, DE. Seroquel (quetiapine): preelinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs. 1996;5:939957.
49. Weiden, PJ. Quetiapine (Seroquel): a new “atypical” antipsychotic. J Pract Psych Behav Health. 1997:3:368374.
50. Misra, LK, Erpenbach, JE, Hamlyn, H, et al. Quetiapine: a new atypical antipsychotic. S D J Med. 1998;51:189193.
51. Beelan, AP, Yeo, KT, Lewis, LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperi-done. Hum Exp Toxicol. 2001;20:215219.
52. Gajwani, P, Pozudo, L, Tesar, GE. QT interval prolongation associated with quetiapine (seroquel) overdose. Psychosomatics. 2000;41:6365.
53. Seeger, TF, Seymour, PA, Schmidt, AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995,275:101113.
54. Keck, P Jr, Buffenstein, A, Ferguson, J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4 week placebo-controlled trial. Psychopharmacology (Bed). 1998;140:173184.
55. Daniel, DG, Zimbroff, DL, Potkin, SG, et al. Ziprasidone 80 and 160 mg/day in the acute exacerbation of schizophrenia and sehizoaffective disorder: a 6 week placebo-controlled trial. Neuropsychopharmacology. 1999;x20:491505.
56. Geodon [package insert]. New York, NY: Pfizer Inc; 2001.
57. Goldman, LS. Medical illness in patients with schizophrenia. J Clin Psychiatry. 1999;60(suppl 21):1015.
58. Gupta, S, Masand, PS, Kaplan, D, Bhandary, A. The relationship between schizophrenia and IBS. Schizophr Res 1997;23:265268.
59. Brown, S, Birtwistle, J, Roe, L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697701.
60. Dixon, L, Postrado, L, Delahanty, J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J New Ment Dis. 1999;187:496502.
61. Pary, RJ, Barton, SN. Communication difficulty of patients with schizophrenia and physical illness. South Med J. 1988;81:489490.
62. Tsuang, MT, Perkins, K, Simpson, JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry. 1983;44:4246.
63. Brown, S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry. 1997;171:502508.
64. Viewig, V, Levenson, J, Pandurangi, A, et al. Medical disorders in schizophrenic patients. Int J Psychiatry Med. 1995;25:137142.
65. Suellen, M, Cutkendall, SM, Mo, J, Jones, JK, et al. Increased cardiovascular dis-ease in schizophrenia. Poster P-001-04 presented at: 7th World Congress of Biological Psychiatry; July 2001; Berlin, Germany.
66. Hennessy, S, Bilker, WB, Santanna, JC, et al. Cardiac arrest risk appears to vary little by choice of antipsychotic drug. Poster NR 507 presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, LA.
67. Miceli, JJ, Smith, M, Robarge, L, et al. The effects of ketoconazole on ziprasidone pharmacokinetics-a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):71S76S.
68. Ziprasidone. Bioltigical Therapies in Psychiatry. 2001;24:22. Study 128-054.

Cardiovascular Side Effects of Novel Antipsychotics

  • Sanjay Gupta, Prakash S. Masand and Ashok J. Kothari


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed